Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Trial Profile

Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RECOURSE
  • Sponsors Taiho Oncology
  • Most Recent Events

    • 20 Oct 2017 According to a Taiho Pharmaceutical media release, based on results of this study Taiho Pharmaceutical announced that Health Canada accepted for review Taiho's New Drug Submission (NDS) and granted priority review status to trifluridine and tipiracil for Refractory Metastatic Colorectal Cancer.
    • 21 Jan 2017 Results of post-hoc analysis assessing time to grade ≥3 adverse events, presented at the 2017 Gastrointestinal Cancers Symposium
    • 21 Jan 2017 Results of post hoc analysis assessing correlations between onset of neutropenia and survival benefit, presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top